European Journal of Nuclear Medicine

, Volume 14, Issue 9, pp 453–462

Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA

  • Adil A. Al-Nahhas
  • Rafaqat A. Jafri
  • Keith E. Britton
  • Kishor Solanki
  • Jamshed Bomanji
  • Steve Mather
  • Melvyn A. Carroll
  • Mazin Al-Janabi
  • Vicenzo Frusciante
  • Boris Ajdinowic
  • Francesco Fiore
  • Solomon Demena
  • Cyril C. Nimmon
Article

DOI: 10.1007/BF00252388

Cite this article as:
Al-Nahhas, A.A., Jafri, R.A., Britton, K.E. et al. Eur J Nucl Med (1988) 14: 453. doi:10.1007/BF00252388

Abstract

The preparation, application and clinical usage of 99mTc-mercaptoacetyltriglycine, MAG3, a tubular secreted compound, is described in the first 225 patients in a phase III study. Image quality, relative renal function, and renal transit times were compared with a 4 fold greater administered activity of 99mTc-DTPA in 11 patients. Correlation coefficients of 0.94 for relative function, 0.83 for parenchymal transit time index and 0.82 for whole kidney transit time index were found. Frusemide responses were similar. 99mTc-MAG3 is an efficacious radiopharmaceutical for routine renal radionuclide studies, giving excellent image quality in patients with hypertension, poor renal function, obstructive nephropathy or a renal transplant.

Key words

99mTc-MAG3 99mTc-DTPA 

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Adil A. Al-Nahhas
    • 1
  • Rafaqat A. Jafri
    • 1
  • Keith E. Britton
    • 1
  • Kishor Solanki
    • 1
  • Jamshed Bomanji
    • 1
  • Steve Mather
    • 1
  • Melvyn A. Carroll
    • 1
  • Mazin Al-Janabi
    • 1
  • Vicenzo Frusciante
    • 1
  • Boris Ajdinowic
    • 1
  • Francesco Fiore
    • 1
  • Solomon Demena
    • 1
  • Cyril C. Nimmon
    • 1
  1. 1.Department of Nuclear MedicineSt. Bartholomew's HospitalLondonUK

Personalised recommendations